Noah AI Industry News

Delivers real-time biopharma news and signals — powered by AI, curated for professionals.

Cigna Reports Strong Q2 Performance, Driven by Evernorth Growth

Cigna Reports Strong Q2 Performance, Driven by Evernorth Growth

Cigna, a major player in the health insurance and pharmacy benefit management sectors, has reported robust second-quarter results, beating investor expectations primarily due to strong growth in its Evernorth health services division. The company's performance comes amid ongoing challenges in the healthcare industry, including persistently elevated medical costs.

NoahAI News8/2/2025
Alnylam's Amvuttra Launch Propels Company to $50B Market Cap

Alnylam's Amvuttra Launch Propels Company to $50B Market Cap

Alnylam Pharmaceuticals has surged past a $50 billion market capitalization, driven by the stellar launch of its rare heart disease medication Amvuttra. The RNA interference biotech's stock price jumped more than 15% following the release of its second-quarter financial results, which significantly exceeded Wall Street expectations.

NoahAI News8/2/2025
Sanofi Expands China Presence with $395M Arrowhead Deal for Rare Metabolic Disease Treatment

Sanofi Expands China Presence with $395M Arrowhead Deal for Rare Metabolic Disease Treatment

Sanofi has struck a $395 million deal with Arrowhead Pharmaceuticals for the China rights to plozasiran, a promising RNA interference (RNAi) therapeutic for rare metabolic diseases. The agreement, announced on August 1, 2025, marks another significant step in Sanofi's expansion strategy in the Chinese pharmaceutical market.

NoahAI News8/2/2025
Merz Aesthetics Shakes Up Leadership Team Amid Evolving Aesthetics Market

Merz Aesthetics Shakes Up Leadership Team Amid Evolving Aesthetics Market

Merz Aesthetics, a key player in the competitive aesthetics industry, has announced significant changes to its sales and marketing leadership structure. The company, known for its Botox rival Xeomin, is positioning itself for growth in the lucrative anti-wrinkle market with these strategic appointments.

NoahAI News8/2/2025
4DMT's Gene Therapy Shows Promise in Diabetic Macular Edema Treatment

4DMT's Gene Therapy Shows Promise in Diabetic Macular Edema Treatment

4D Molecular Therapeutics (4DMT) has reported encouraging 60-week data from its phase 2 trial of 4D-150, a gene therapy designed to treat diabetic macular edema (DME). The results, presented at the Annual American Society of Retina Specialists Scientific Meeting, demonstrate sustained efficacy and a significant reduction in the need for supplemental injections, potentially offering a breakthrough in DME management.

NoahAI News8/1/2025
AbbVie's Potential Billion-Dollar Psychedelics Deal Signals Industry Shift

AbbVie's Potential Billion-Dollar Psychedelics Deal Signals Industry Shift

In a move that could reshape the landscape of psychedelic drug development, pharmaceutical giant AbbVie is reportedly in talks to acquire Gilgamesh Pharmaceuticals for a sum that may reach into the billions. This potential deal has sent ripples through the biotech sector, lifting share prices of psychedelics-focused companies and signaling a possible sea change in how big pharma views this emerging field of mental health treatment.

NoahAI News8/1/2025
FDA Approvals and Rejections Shape Pharmaceutical Landscape in July

FDA Approvals and Rejections Shape Pharmaceutical Landscape in July

The U.S. Food and Drug Administration (FDA) made several significant decisions in July, issuing approvals for new drugs and expanded indications while also rejecting some high-profile applications. These rulings have far-reaching implications for patients, pharmaceutical companies, and the broader healthcare industry.

NoahAI News8/1/2025
BMS's Cobenfy Faces Uncertain Future Amid Mixed Clinical Results

BMS's Cobenfy Faces Uncertain Future Amid Mixed Clinical Results

Bristol Myers Squibb's (BMS) schizophrenia drug Cobenfy is facing an uncertain future following disappointing results in a Phase III clinical trial. The pharmaceutical giant is now reassessing the drug's potential while awaiting results from ongoing studies in Alzheimer's disease psychosis.

NoahAI News8/1/2025
Sanofi Anticipates Limited Impact from Potential EU Drug Tariffs in 2025

Sanofi Anticipates Limited Impact from Potential EU Drug Tariffs in 2025

French pharmaceutical giant Sanofi has expressed confidence that potential tariffs on drugs imported from the European Union will have minimal effect on its finances in 2025. This assurance comes amid ongoing uncertainty surrounding trade negotiations between the United States and the EU.

NoahAI News8/1/2025
AbbVie's Skyrizi and Rinvoq Set to Surpass Humira's Peak Sales, Driving Strong Q2 Performance

AbbVie's Skyrizi and Rinvoq Set to Surpass Humira's Peak Sales, Driving Strong Q2 Performance

AbbVie, the global biopharmaceutical company, has reported exceptional second-quarter results, largely driven by the stellar performance of its immunology drugs Skyrizi and Rinvoq. The company's earnings have exceeded expectations, prompting a revision of its full-year guidance and showcasing a successful transition from its former blockbuster, Humira.

NoahAI News8/1/2025
Autonomous Robotic Surgery and Advanced Cardiac Mapping: Breakthroughs in Medical Technology

Autonomous Robotic Surgery and Advanced Cardiac Mapping: Breakthroughs in Medical Technology

In a significant leap forward for robotic surgery and cardiac care, two companies have announced major milestones in their respective fields. Monogram Technologies has successfully performed the first fully autonomous robotic knee replacement, while Stereotaxis has received FDA clearance for a new robotic mapping catheter, marking important advancements in medical technology.

NoahAI News8/1/2025
Lilly's Mounjaro Shows Promise in Cardiovascular Outcomes Trial, Matching Trulicity's Performance

Lilly's Mounjaro Shows Promise in Cardiovascular Outcomes Trial, Matching Trulicity's Performance

Eli Lilly's blockbuster diabetes drug Mounjaro (tirzepatide) has demonstrated its cardiovascular benefits in a large-scale Phase III trial, positioning the company to seek expanded approval for reducing heart risks in patients with type 2 diabetes.

NoahAI News8/1/2025
«1234...67»